Grote TH - Search Results

1

Secondary immune thrombocytopenia (ITP) as an initial presentation of Whipple's disease.

Priest DH, Grote TH, Staley SL, Berger WS, Norman ES, Smith BS. Priest DH, et al. Among authors: grote th. IDCases. 2017 Jun 28;12:e4-e6. doi: 10.1016/j.idcr.2017.05.010. eCollection 2018. IDCases. 2017. PMID: 29942787 Free PMC article.

2

Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group.

Navari RM, Reinhardt RR, Gralla RJ, Kris MG, Hesketh PJ, Khojasteh A, Kindler H, Grote TH, Pendergrass K, Grunberg SM, Carides AD, Gertz BJ. Navari RM, et al. Among authors: grote th. N Engl J Med. 1999 Jan 21;340(3):190-5. doi: 10.1056/NEJM199901213400304. N Engl J Med. 1999. PMID: 9917226 Free article. Clinical Trial.

3

Rationale for the use of a single fixed intravenous dolasetron dose for the prevention of cisplatin-induced nausea and vomiting. Pooled analysis of 14 clinical trials.

Whitmore JB, Kris MG, Hesketh PJ, Grote TH, DuBois DM, Cramer MB, Hahne WF. Whitmore JB, et al. Among authors: grote th. Support Care Cancer. 1998 Sep;6(5):473-8. doi: 10.1007/s005200050197. Support Care Cancer. 1998. PMID: 9773466

4

Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone.

Kris MG, Pendergrass KB, Navari RM, Grote TH, Nelson AM, Thomas V, Ferguson BB, Allman DS, Pizzo BA, Baker TW, Fernando IJ, Chernoff SB. Kris MG, et al. Among authors: grote th. J Clin Oncol. 1997 May;15(5):2135-8. doi: 10.1200/JCO.1997.15.5.2135. J Clin Oncol. 1997. PMID: 9164228 Clinical Trial.

5

Randomized, double blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy. Oral Dolasetron Dose-Response Study Group.

Rubenstein EB, Gralla RJ, Hainsworth JD, Hesketh PJ, Grote TH, Modiano MR, Khojasteh A, Kalman LA, Benedict CR, Hahne WF. Rubenstein EB, et al. Among authors: grote th. Cancer. 1997 Mar 15;79(6):1216-24. Cancer. 1997. PMID: 9070501 Clinical Trial.

6

Oral dolasetron mesylate in patients receiving moderately emetogenic platinum-containing chemotherapy. Oral Dolasetron Dose Response Study Group.

Grote TH, Pineda LF, Figlin RA, Pendergrass KB, Hesketh PJ, Karlan BY, Reeves JA, Porter LL, Benedict CR, Hahne WF. Grote TH, et al. Cancer J Sci Am. 1997 Jan-Feb;3(1):45-51. Cancer J Sci Am. 1997. PMID: 9072308 Clinical Trial.

7

High-dose 24-hour infusion of 5-fluorouracil in metastatic prostate cancer. A phase II trial of the Piedmont Oncology Association.

Atkins JN, Muss HB, Case D, Brockschmidt J, Schnell FM, O'Rourke M, Grote TH, West JH, Anthony S, Stanley V. Atkins JN, et al. Among authors: grote th. Am J Clin Oncol. 1991 Dec;14(6):526-9. doi: 10.1097/00000421-199112000-00012. Am J Clin Oncol. 1991. PMID: 1957840 Clinical Trial.

8

Primary lymphoma of the central nervous system. A report of 20 cases and a review of the literature.

Grote TH, Grosh WW, List AF, Wiley R, Cousar JB, Johnson DH. Grote TH, et al. Am J Clin Oncol. 1989 Apr;12(2):93-100. doi: 10.1097/00000421-198904000-00001. Am J Clin Oncol. 1989. PMID: 2650529 Review.

9

Atypical carcinoid of the lung. A distinct clinicopathologic entity.

Grote TH, Macon WR, Davis B, Greco FA, Johnson DH. Grote TH, et al. Chest. 1988 Feb;93(2):370-5. doi: 10.1378/chest.93.2.370. Chest. 1988. PMID: 2827965

10

Hypercalcemia and elevated serum calcitriol in a patient with seminoma.

Grote TH, Hainsworth JD. Grote TH, et al. Arch Intern Med. 1987 Dec;147(12):2212-3. Arch Intern Med. 1987. PMID: 3689074

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

10 results

Search Page

Filters